期刊文献+

倍他乐克治疗扩张型心肌病重度心力衰竭疗效观察 被引量:2

Efficacy of treatment with Betaloc on congestive heart failure in patients with dilated cardiomyopathy
下载PDF
导出
摘要 目的:观察倍他乐克治疗扩张型心肌病心力衰竭的长期疗效。方法:扩张型心肌病重度心力衰竭患者27例,分为倍他乐克治疗组15例,常规组12例,两组病例给予氨力农、洋地黄、利尿剂等治疗,控制急性心力衰竭,病情稳定1周以上,常规治疗组口服地高辛、血管转换酶抑制剂(ACEI)、利尿剂;治疗组在此基础上加用倍他乐克,并根据病情逐步加大剂量,最高剂量为50mg,2次/日,5年后倍他乐克平均剂量达23.5±2.5mg。结果:5年后临床心功能(NYHA)及心脏超声心功能缩短百分率(FS)、射血分数(EF)对比,同组前后对比倍他乐克组差异显著(P<0.05)。常规组无显著差异(P>0.05)。5年后心功能、再住院率、生存率组间对比差异显著(P<0.05)。结论:与常规治疗组对比,长期应用倍他乐克可以改善血流动力学、提高运动耐量、生活质量、减少猝死率、延长生存年限。
作者 杨青
出处 《上海医药》 CAS 2005年第4期177-178,共2页 Shanghai Medical & Pharmaceutical Journal
  • 引文网络
  • 相关文献

参考文献8

  • 1Esler M, Kaye D, Lambert G, et al. Adrenergic nervous system in heart failure. Am J Caurdiol,1997,80(Suppl) :7L.
  • 2Bristow MR. Mechanism Of action of beta - blocking agent in heart failure. Am J Cardiol,1997,80(3) :26L.
  • 3MERIT HF. Study Group. Efrect Of metoprolOl CR/XL in c11ronic heart failure: Metoprolol CR/XL Randomised Intervention Trialin COngestive Heart Failure ( MERT - HF). Lancet, 1999,353 (8):2001.
  • 4Santostasi G, Fraccarouo D, Dorigo P, et al. Early reduction in plasma norepirephineduring beta - blocking therapy with metoprolol in chronic heart failure. J Card Fail,1998,4(6) :177.
  • 5Waagstein F, Wahlquist I, Andensson B, et al. Metoprolol prevents leR ventricular diltation and increase ei ection fraction to the same extent in idiopathic and ischemic cardiomyopathy. Eur Heart J, 1998,19(Suppl) :307.
  • 6Antz -M. Cappator Ro Kuc KH. Metoprolo versus sotalol in the treatment of sustailled ventricular tachycardia. J Cardiovasc Phatmocol, 1995,26 (3) :627.
  • 7The International Steering Committee. Rational design and organizotion of Metoprolol CR/XL Randomized Intervention 11rail in Heart Failure(MERIT- HF). Am J Cardiol,1 997,80(9B) ;54J.
  • 8Goldstein S. Clinical studies on beta blockers and heart failure preceding the MERT- HF Trial, Metoprolol CR/XL Randomized Intervention nial in Heart Failure. Am J Cardiol, 1997,80 (5):50J.

同被引文献19

二级引证文献7

;
使用帮助 返回顶部